Makrocare In Ppt
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Makrocare In Ppt as PDF for free.
More details
- Words: 985
- Pages: 14
Me An Asset! An Asset! An Asset! Saumitra Rahatekar [email protected] +1 (848) 248 9998 02/23/09
Current Scenario •
Obama administration supporting Stem cell - will translate into more stem cell based therapeutics (Clinical Trials) Obama Admin is having $300 billion dedicated to EHR for increasing Healthcare efficiency
•
Advent of Biogenerics will bring in more BA/BE studies
•
More insurance companies are doing epidemiological studies on life style, effect of diet et.al Combinatorial Chemistry has increased the number of compounds to be tested
•
M & A are combining pipelines Personalized medicine
Current Scenarion (contd.) •
Sentinel act of monitoring SAEs of drugs in market is new opportunity for Makrocare Adaptive trials for cutting costs and selecting doses
•
Global operation for Clinical Research
•
Abandoning $800 million R & D for a drug and moving to sub $300 million will lead to more outsourcing
•
Imaging related Clinical Research services will grow @ 40 %
•
Adv Makrocare End to end solutions (So less of information transfer issues) Oracle CDMA, EDC, IVRS and back end IT capability focusing on interoperability
•
This will help in doing Adaptive trials
•
Presence in future mecca of Clinical Research - India , gives us Sun advantage as well allowing to work 24X7
•
Presence in all major Therapy areas Global Presence - US, EU, Japan, India Each day in getting the product in the market delay costs Pharma about $7 million per day, Makrocare is well positioned to reduce this
Business ideas •
Its costs nearly 40 cents to manage per $1 worth outsourced services Bringing down these transaction costs for Pharma companies
•
Reducing data management costs
•
To see the world through partner’s eyes and forming joint term goals New Business model involving partnerships with companies having promising drugs but less finance to take it through, and getting royalties from sales
•
Introducing micro-dosing for faster human trials thus cutting costs for partner Focusing on protein therapeutics and nucleotides * - elaborated in forthcoming slides
Business ideas (contd.) Focusing on Animal Therapeutics market* Focusing on universities* Focusing on NGOs*
Keeping tab on John Hopkins, Cleveland Clinic, Mayo Clinic, Mass Gener Hospital for their best practices and patient outsourcing
•
Operations flexibility by using Sponsor’s recommended SOPs
•
Creating online communities for getting feedback on services rendered
•
Making customer feedback easier for customers
* - elaborated in forthcoming slides
Business ideas (contd.) •
Sharing details of # of projects a typical CRA handled simultaneously, with the partner Integration of Makrocare’s results/reports with clients existing infrastructure for better (real time) decision making on behalf of client
•
Considering Build-Operate-Transfer model for companies not having presence in India
•
Making reports smart phone enabled (read - iPhone)
•
Adopting ‘Freemium’ by doling out free reports thus gaining top of mind recall
Animal Therapeutics & Diagnostics •
Important Stats for Animal Therapeutics and Diagnostics Total market - $22 billion
•
Growth - 8 % p.a
•
Total households in US with atleast one pet - 70 million Top 4 companies - Pfizer, Wyeth, Merial, Intervet
•
Trends - Vaccination, Animal Obesity and age related diseases
Universities Tech transfer University
Amount
Comments
NYU
$650 mln
Remicade MAb- J & J
Columbia
$135 mln
University of California
$97.6 mln
Northwestern University
$85 mln
Pfizer’s Fibromylgia drug - Lyrica
$71.2 mln
Medical device to Kinetic Concepts
Wake Forest University Massachusetts General Hospital Beckman Research Emory university University of Minnesota University of Rochester
$346 mln $118 mln $611 mln
Giliead’s HIV - Emtriva
$63.3 mln $53.3 mln
Arthritis drug licensing
NGOs untapped potential •
Cystic Fibrosis Foundation pours $76 million in Vertex Pharma for Cystic Fibrosis drug Leukemia & Lymphoma Society invested $3.7 million in Celator Pharma for funding mid stage clinical trial for drug on Myeloid Leukemia
•
National Multiple Sclerosis Society paid $1 million for Apitope International NV - Belgian Company
•
Juvenile Diabetes Research foundation and Osiris Therapeutics - $4 million for Stem cell based Diabetes treatment
•
Michael J Fox commits $6 million for 3 Parkinson disease clinical trials
Recommendations Nilesh Gupta - President Advanced Market - Lupin Pharma- “Saumitra is an excellent sales person”. (Uses Thomson Pharma and Horizon Global) - This recommendation was after I sold Lupin $ 140,000 product. Sanjay Bettadpura, - Head Life Science Vertical - Edutech India - “Saumitra brings in an infectious freshness and enthusiasm to the sales and marketing process. Highly creative, and always looking for smarter ways to close deals, he builds great rapport with his customers and genuinely looks to solving their problems rather than just making a sale. Always up-to-date about the industry , his domain knowledge in life sciences is a great plus. As a part of my team, he was always the first to achieve his targets and needed little guidance from me. He is self motivated, takes initiatives and has good problem solving capabilities.His passion for the industry and single mindedness to provide value to customers make a him a great sales and business development person.” Satheesh Muttathil - Sales training manager - Schering Plough - “Saumitra is enterprising and professional in his approach and is very innovative while executing his commitments. He is highly detail oriented and exhibits
Why me •
MBA in Biotechnology with 6 years of experience in Life Sciences Well versed with industry standards - CDISC, 21 CFR Part 11,IVRS, HL-7, GCP, Ethics, eCTD et.al
•
Doing certified course on SAS Clinical and Oracle Clinical Data Management system
•
Excellent presentation and communication skills Good networking capabilities
•
Uses Web2.0 tools like Linkedin, Twitter for sales leads
•
Sold Centerwatch services to CROs Tremendous appetite for knowledge
•
Understands business - patronize Wall Street Journal and Harvard Business Review
Why me (contd.) Proactive Never say die attitude Out of box thinking Passionate towards work Diploma in Supply Chain Management
Saumitra Rahatekar [email protected] +1(848) 248 9998 +1(848) 248 9998 +1(848) 248 9998
Current Scenario •
Obama administration supporting Stem cell - will translate into more stem cell based therapeutics (Clinical Trials) Obama Admin is having $300 billion dedicated to EHR for increasing Healthcare efficiency
•
Advent of Biogenerics will bring in more BA/BE studies
•
More insurance companies are doing epidemiological studies on life style, effect of diet et.al Combinatorial Chemistry has increased the number of compounds to be tested
•
M & A are combining pipelines Personalized medicine
Current Scenarion (contd.) •
Sentinel act of monitoring SAEs of drugs in market is new opportunity for Makrocare Adaptive trials for cutting costs and selecting doses
•
Global operation for Clinical Research
•
Abandoning $800 million R & D for a drug and moving to sub $300 million will lead to more outsourcing
•
Imaging related Clinical Research services will grow @ 40 %
•
Adv Makrocare End to end solutions (So less of information transfer issues) Oracle CDMA, EDC, IVRS and back end IT capability focusing on interoperability
•
This will help in doing Adaptive trials
•
Presence in future mecca of Clinical Research - India , gives us Sun advantage as well allowing to work 24X7
•
Presence in all major Therapy areas Global Presence - US, EU, Japan, India Each day in getting the product in the market delay costs Pharma about $7 million per day, Makrocare is well positioned to reduce this
Business ideas •
Its costs nearly 40 cents to manage per $1 worth outsourced services Bringing down these transaction costs for Pharma companies
•
Reducing data management costs
•
To see the world through partner’s eyes and forming joint term goals New Business model involving partnerships with companies having promising drugs but less finance to take it through, and getting royalties from sales
•
Introducing micro-dosing for faster human trials thus cutting costs for partner Focusing on protein therapeutics and nucleotides * - elaborated in forthcoming slides
Business ideas (contd.) Focusing on Animal Therapeutics market* Focusing on universities* Focusing on NGOs*
Keeping tab on John Hopkins, Cleveland Clinic, Mayo Clinic, Mass Gener Hospital for their best practices and patient outsourcing
•
Operations flexibility by using Sponsor’s recommended SOPs
•
Creating online communities for getting feedback on services rendered
•
Making customer feedback easier for customers
* - elaborated in forthcoming slides
Business ideas (contd.) •
Sharing details of # of projects a typical CRA handled simultaneously, with the partner Integration of Makrocare’s results/reports with clients existing infrastructure for better (real time) decision making on behalf of client
•
Considering Build-Operate-Transfer model for companies not having presence in India
•
Making reports smart phone enabled (read - iPhone)
•
Adopting ‘Freemium’ by doling out free reports thus gaining top of mind recall
Animal Therapeutics & Diagnostics •
Important Stats for Animal Therapeutics and Diagnostics Total market - $22 billion
•
Growth - 8 % p.a
•
Total households in US with atleast one pet - 70 million Top 4 companies - Pfizer, Wyeth, Merial, Intervet
•
Trends - Vaccination, Animal Obesity and age related diseases
Universities Tech transfer University
Amount
Comments
NYU
$650 mln
Remicade MAb- J & J
Columbia
$135 mln
University of California
$97.6 mln
Northwestern University
$85 mln
Pfizer’s Fibromylgia drug - Lyrica
$71.2 mln
Medical device to Kinetic Concepts
Wake Forest University Massachusetts General Hospital Beckman Research Emory university University of Minnesota University of Rochester
$346 mln $118 mln $611 mln
Giliead’s HIV - Emtriva
$63.3 mln $53.3 mln
Arthritis drug licensing
NGOs untapped potential •
Cystic Fibrosis Foundation pours $76 million in Vertex Pharma for Cystic Fibrosis drug Leukemia & Lymphoma Society invested $3.7 million in Celator Pharma for funding mid stage clinical trial for drug on Myeloid Leukemia
•
National Multiple Sclerosis Society paid $1 million for Apitope International NV - Belgian Company
•
Juvenile Diabetes Research foundation and Osiris Therapeutics - $4 million for Stem cell based Diabetes treatment
•
Michael J Fox commits $6 million for 3 Parkinson disease clinical trials
Recommendations Nilesh Gupta - President Advanced Market - Lupin Pharma- “Saumitra is an excellent sales person”. (Uses Thomson Pharma and Horizon Global) - This recommendation was after I sold Lupin $ 140,000 product. Sanjay Bettadpura, - Head Life Science Vertical - Edutech India - “Saumitra brings in an infectious freshness and enthusiasm to the sales and marketing process. Highly creative, and always looking for smarter ways to close deals, he builds great rapport with his customers and genuinely looks to solving their problems rather than just making a sale. Always up-to-date about the industry , his domain knowledge in life sciences is a great plus. As a part of my team, he was always the first to achieve his targets and needed little guidance from me. He is self motivated, takes initiatives and has good problem solving capabilities.His passion for the industry and single mindedness to provide value to customers make a him a great sales and business development person.” Satheesh Muttathil - Sales training manager - Schering Plough - “Saumitra is enterprising and professional in his approach and is very innovative while executing his commitments. He is highly detail oriented and exhibits
Why me •
MBA in Biotechnology with 6 years of experience in Life Sciences Well versed with industry standards - CDISC, 21 CFR Part 11,IVRS, HL-7, GCP, Ethics, eCTD et.al
•
Doing certified course on SAS Clinical and Oracle Clinical Data Management system
•
Excellent presentation and communication skills Good networking capabilities
•
Uses Web2.0 tools like Linkedin, Twitter for sales leads
•
Sold Centerwatch services to CROs Tremendous appetite for knowledge
•
Understands business - patronize Wall Street Journal and Harvard Business Review
Why me (contd.) Proactive Never say die attitude Out of box thinking Passionate towards work Diploma in Supply Chain Management
Saumitra Rahatekar [email protected] +1(848) 248 9998 +1(848) 248 9998 +1(848) 248 9998
Related Documents
Makrocare In Ppt
May 2020 1
Makrocare Newsletter
May 2020 2
Ppt-pygmalion In Management
July 2020 1
Ppt Electricity In India
May 2020 11
Open Source In Ppt
November 2019 32